BRIEF published on 11/10/2025 at 13:17, 24 days 16 hours ago Schloss Wachenheim AG: Positive Outlook with Increased Price Target Schloss Wachenheim AG Price Target Increase Q1 2025/26 Results France Segment Recovery Bond Yield Impacts
PRESS RELEASE published on 11/10/2025 at 13:12, 24 days 16 hours ago Original-Research: Schloss Wachenheim AG (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research upgrades Schloss Wachenheim AG, recommends Buy with target price of €20 after strong Q1 25/26 results. Sales up 3.5% to €106.0m First Berlin Equity Research Buy Recommendation Schloss Wachenheim AG Q1 25/26 Results €20 Target Price
BRIEF published on 09/30/2025 at 11:03, 2 months 4 days ago Schloss Wachenheim AG: Buy Rating Reiterated Despite Challenges Financial Results Buy Recommendation Sales Growth Schloss Wachenheim Market Forecast
PRESS RELEASE published on 09/30/2025 at 10:58, 2 months 4 days ago Original-Research: Schloss Wachenheim AG (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research updates Schloss Wachenheim AG analysis post-2024/25 Annual report, maintains BUY rating, lowers price target to €19 First Berlin Equity Research BUY Rating Analysis Price Target Schloss Wachenheim AG
BRIEF published on 05/12/2025 at 13:11, 6 months 23 days ago Schloss Wachenheim AG: Sales Decline but Optimism for Q4 Financial Performance Buy Recommendation Sales Decline Schloss Wachenheim AG Q4 Rebound
PRESS RELEASE published on 05/12/2025 at 13:06, 6 months 23 days ago Original-Research: Schloss Wachenheim AG (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research GmbH releases a research update on Schloss Wachenheim AG, maintaining a Buy recommendation with a lowered price target of €21 from €22 First Berlin Equity Research Buy Recommendation Price Target Schloss Wachenheim AG Q3 24/25 Results
BRIEF published on 02/24/2025 at 14:56, 9 months 8 days ago Schloss Wachenheim AG Sees Strong EBIT Growth Amid Lower Energy Costs Schloss Wachenheim AG EBIT Growth Market Forecast Sales Performance Energy Costs
PRESS RELEASE published on 02/24/2025 at 14:51, 9 months 8 days ago Original-Research: Schloss Wachenheim AG (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research reaffirms Buy rating on Schloss Wachenheim AG with a target price of EUR 22 following Q2 24/25 results showing sales growth and EBIT increase First Berlin Equity Research BUY Rating Schloss Wachenheim AG EUR 22 Q2 24/25
BRIEF published on 11/11/2024 at 15:36, 1 year ago Schloss Wachenheim AG: First Berlin Reiterates Buy Rating First Berlin Equity Research Sales Projections Schloss Wachenheim AG Consumer Confidence Q1 24/25 Performance
PRESS RELEASE published on 11/11/2024 at 15:31, 1 year ago Original-Research: Schloss Wachenheim AG (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research reiterates Buy rating and €22 price target for Schloss Wachenheim AG based on Q1 24/25 results First Berlin Equity Research BUY Rating Schloss Wachenheim AG Q1 24/25 Results €22 Price Target
Published on 12/05/2025 at 02:35, 2 hours 49 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 4 hours 24 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 6 hours 19 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 6 hours 24 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 1 hour 54 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 5 hours 33 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 8 hours 59 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 9 hours 9 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 10 hours 14 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:00, 11 hours 24 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 11 hours 39 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 11 hours 40 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 22 hours 23 minutes ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 11 hours ago Declaration of voting rights at the end of November 2025
